Tango Therapeutics, Inc. (TNGX) stock
TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30128% above fair value
$22.11−2.06 (-8.52%)
Close on Nov 17, 2026Market cap $3.73BP/E –Yield –
Tango Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Tango Therapeutics's price to sales ratio was 80.5× on Nov 11, 2026, against 18.3× a year earlier. Over the last 5 years it ranged from 3.5× to 80.5×, with a median of 20.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 80.5× | +65.6 |
| 2025 | Dec 31, 2025 | 14.9× | +7.2 |
| 2024 | Dec 31, 2024 | 7.7× | −19.2 |
| 2023 | Dec 29, 2023 | 26.9× | +0.5 |
| 2022 | Dec 30, 2022 | 26.4× | +2.8 |
| 2021 | Dec 31, 2021 | 23.7× | – |
See a number that looks wrong?